Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A rand, doubleblind, activecontrolled, parallel-grp,singledummy, multicenter,12 wk study to assess the effic.andsafety of symbicort pmdi 2x160/4.5mcg qd compared to symb. pmdi 2x80/4.5mcg qd, symb. pmdi 2x80/4.5mcg bid and to budesonide pmdi 2x160 mcg qd in asthmatic sub's12yrs and over

Next Previous
Search
Trial Profile

A rand, doubleblind, activecontrolled, parallel-grp,singledummy, multicenter,12 wk study to assess the effic.andsafety of symbicort pmdi 2x160/4.5mcg qd compared to symb. pmdi 2x80/4.5mcg qd, symb. pmdi 2x80/4.5mcg bid and to budesonide pmdi 2x160 mcg qd in asthmatic sub's12yrs and over

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 01 Jul 2009 Efficacy results were reported in Annals of Allergy, Asthma & Immunology.
    • 18 Apr 2008 New trial record.
    • 18 Mar 2008 Tolerability results presented at AAAAI in 2008

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top